



CCBIO

CAPTURING CANCER COMPLEXITY
AND CLINICAL CHALLENGES

CCBIO ANNUAL SYMPOSIUM

SCIENTIFIC PROGRAMS 2013 – 2025



Centre for
Cancer Biomarkers
Norwegian Centre of Excellence – University of Bergen



The Research Council of Norway



13th CCBIO ANNUAL SYMPOSIUM – MAY 13-14, 2025

Solstrand Hotel & Bad // Bergen // Norway

DAY 1: TUESDAY MAY 13, 2025

08:30-10:00 REGISTRATION

10:15-10:30 **Lars A. Akslen** (Director of CCBIO): Welcome and Opening

Session 1. Chair: **Carina Strell** (Co-Director of CCBIO)

10:30-11:15 **Sir David Lane** (Stockholm): Progress and challenges in understanding p53

11:15-11:45 **Eva Hellström-Lindberg** (Stockholm): Splice factor mutations in myeloid neoplasms

11:45-13:30 LUNCH AND POSTER SESSION I

Session 2. Chair: **Lars A. Akslen**

13:30-14:00 **Olav Engebraaten** (Oslo): NeoAva: Neoadjuvant breast cancer treatment translated into biomarkers for antiangiogenic therapy

14:00-14:30 **Theodoros Foukakis** (Stockholm): Multi-omic profiling reveals predictive biomarkers of response to antibody-drug conjugates in HER2-positive breast cancer

14.30-15:15 COFFEE BREAK

Session 3. Chair: **Bjørn Tore Gjertsen**

15:15-15:35 **Spiros Kotopoulos** (Neoety): Academia vs Industry: The similarities, the differences and why we need each other

15:35-15:55 **Katja Vetvik** (Thelper): My journey from science to biotechnology: Navigating opportunities and challenges in Norway's funding climate

15:55-16:15 **Lars Prestegarden** (Cytovation): Drugging the undruggable: From data-algorithms to patient benefit

16:15-16:35 Discussion

18:00 APERITIF

19:00 DINNER



DAY 2: WEDNESDAY MAY 14, 2025

Session 4. Chair: Arne Östman

- 09:00-09:30 **Julia Tutzauer** (Stockholm): Tamoxifen-predictive gene expression in ER+ breast cancer – insights from 20 years of follow-up in the Stockholm trials
- 09:30-10:00 **Anna Dimberg** (Uppsala): Optimizing vascular function to promote anti-tumor immunity in glioblastoma
- 10:00-10:30 **Steinar Thoresen** (Oslo): How can Nordic cancer registries be used for innovative applications of Real-World Evidence
- 10:30-11:15 COFFEE BREAK

Session 5. Chairs: Katrin Kleinmanns & Line Bjørge

- 11:15-12:15 Speed presentations by young investigators

Session 6. Chairs: Rammah Elnour & Line Bjørge

Short presentations by industry: Developments and future possibilities

- 12:15-12:35 **Hege Edvardsen** (GSK): The road to the industry – practical info to navigate the landscape and identify opportunities
- 12:35-12:45 **Elisabeth Jarnæss** (AbbVie): AbbVie – a career journey in our industry
- 12:45-12:55 **Ana Kucera** (AstraZeneca): Shaping the future of healthcare: Careers at AstraZeneca
- 13:00-15:00 LUNCH AND POSTER SESSION II

Session 7. Chair: Camilla Krakstad

- 15:00-15:30 **Jean Albregues** (Nice): Neutrophil extracellular traps formed during chemotherapy confer treatment resistance
- 15:30-16:00 **Camilla Krakstad** (Bergen): A novel role of vimentin in endometrial cancer progression
- 16:00-16:15 **Line Bjørge** (Co-Director of CCBIO): Closing remarks



12th CCBIO ANNUAL SYMPOSIUM – MAY 14-15, 2024

Solstrand Hotel & Bad // Bergen // Norway

DAY 1: TUESDAY MAY 14, 2024

09:00-10:10 REGISTRATION

10:15-10:30 **Lars A. Akslen** (Director of CCBIO): Welcome and Opening

Session 1. Chair: **Carina Strell**

10:30-11:15 **Raza Ali** (Cambridge): Charting the intact breast tumour microenvironment

11:15-11:45 **Patrick Micke** (Uppsala): Functional diagnostics for optimised lung cancer therapy

11:45-13:30 LUNCH AND POSTER SESSION I

Session 2. Chair: **Jim Lorens**

13:30-14:00 **Therese Sørli** (Oslo): Spatial heterogeneity in DCIS aligns with intrinsic subtypes

14:00-14:30 **Rolf Brekken** (Dallas): Phosphatidylserine - a marker of the tumor microenvironment and much more

14.30-15:15 COFFEE BREAK

Session 3. Chair: **Roger Strand. Global perspectives on cancer**

15:15-15:40 **Kjell-Arne Johansson** (Bergen): Cancer interventions and health priorities in a global perspective using "FairChoices: DCP Analytics Tool"

15:40-16:00 **Daniela Costea** (Bergen): Reflections on cancer research for the global north and the global south

16:00-16:35 Panel conversation: **Danilo Milanes Zambrano** (Kigali), **Karpal Singh** (Dar es Salaam), **Kjell-Arne Johansson**, **Daniela Costea**, and **John Cairns** (London)

18:00 POSTERS & PROSECCO

19:00 DINNER



DAY 2: WEDNESDAY MAY 15, 2024

Session 4. Chair: Oddbjørn Straume

09:00-09:45 **Göran Jönsson** (Lund): Understanding response to immune checkpoint blockade in melanoma

09:45-10:15 **Randy S. Watnick** (Boston): Discovery of a novel signalling pathway mediating immunosuppression in solid tumors

10:15-11:30 COFFEE BREAK

Session 5. Chairs: Katrin Kleinmanns & Line Bjørge

11:30-12:30 Speed presentations by young investigators

12:30-14:30 LUNCH AND POSTER SESSION II

Session 6. Chair: Elisabeth Wik

14:30-15:00 **Sandra Ryeom** (New York): Neuroimmune crosstalk in the gastric cancer microenvironment

15:00-15:30 **Anna Vähärautio** (Helsinki): Tracing back primed resistance in cancer

15:30-16:00 COFFEE BREAK

Session 7. Chair: Line Bjørge

16:00-16:30 **Linda Lindström** (Stockholm): Insights into the heterogeneity of ER-positive breast cancer - long-term risk, endocrine treatment benefit and intra-tumor heterogeneity

16:30-17:00 **Fran Balkwill** (London): Modelling and targeting the tumour microenvironment of high-grade serous ovarian cancer

17:00-17:15 **Line Bjørge** (Co-Director of CCBIO): Closing remarks



11th CCBIO ANNUAL SYMPOSIUM – MAY 8-10, 2023

Solstrand Hotel & Bad // Bergen // Norway

DAY 1: MONDAY MAY 8, 2023

10:00-11:30 REGISTRATION AND COFFEE

11:30-13:00 LUNCH

13:00-13:15 **Lars A. Akslen** (Director of CCBIO): Welcome and Opening

Session 1. Chair: **Arne Östman**

13:15-14:00 **Alexander Swarbrick** (Darlinghurst): Parsing breast cancer ecosystems with cellular genomics

14:00-14:45 **Ian Mills** (Oxford): Spatial lessons from prostate cancer research

14:45-15:30 COFFEE BREAK

Session 2. Chair: **Line Bjørge**

15:30-16:00 **Iain McNeish** (London): Ovarian cancer and copy number alterations

16:00-16:30 **Anniina Färkkilä** (Helsinki): How HRD/BRCA status influences the ovarian cancer TME

16:30-17:00 **Frédéric Amant** (Leuven/Amsterdam): How to organize translational cancer research, including the importance of preclinical models

19:30 DINNER

DAY 2: TUESDAY MAY 9, 2023

Session 3. Chair: **Carina Strell**

09:00-09:45 **Robert D'Amato** (Boston): Deciphering the mechanism of tumor acquired resistance to antiangiogenic therapies

09:45-10:15 **Michael Rogers** (Boston): What happens when an endothelial cell loses its compass? A role for CMG2 in chemotaxis

10:15-11:15 COFFEE BREAK

Session 4. Chairs: **Katrin Kleinmanns and Line Bjørge**

11:15-12:30 Speed presentations by young investigators

12:30-14:30 LUNCH AND POSTER SESSION I

Session 5. Chair: **Anne Blanchard**

14:30-15:45 Responsible clinical trials in the age of personalized medicine. Panel: **Linn Getz**, NTNU; **Caroline Engen**, Neuro-SysMed/UiB; **Line Bjørge** and **Karen Rosnes Gissum**, CCBIO.

15:45-16:15 COFFEE BREAK

Session 6. Chair: **Agnete Engelsen**

16:15-16:45 **Stephane Terry** (Paris): Role of hypoxia, EMT and AXL in cancer immune escape

16:45-17:15 **Ingrid Hedenfalk** (Lund): Exploring the normal-like subtype of breast cancer

19:30 DINNER

DAY 3: WEDNESDAY MAY 10, 2023

Session 7. Chair: Karl-Henning Kalland

09:00-09:45 **Klaus Pantel** (Hamburg): Liquid biopsy: From discovery to clinical implementation

09:45-10:15 **Catherine Alix-Panabières** (Montpellier): Metastasis-initiator circulating tumor cells in colon and breast cancers

10:15-10:45 COFFEE BREAK

Session 8. Chair: Jim Lorens

10:45-11:15 **Mark LaBarge** (Duarte, CA): Integrating noise into a signal: loss of lineage specificity presages breast cancer susceptibility

11:15-11:45 **Amy LeBlanc** (Bethesda, MD): The US National Cancer Institute's Comparative Oncology Program: Contributions to cancer research and drug development

11:45-12:15 **Benno Schwikowski** (Paris): How to build computational approaches to discover causal paths in cancer

12:15-12:45 **Rameen Beroukhim** (Boston): Detecting effects of SVs on cancer cellular fitness

12:45-14:45 LUNCH AND POSTER SESSION II

Session 9. Chair: Bjørn Tore Gjertsen

14:45-15:15 **Caroline Heckman** (Helsinki): Functional precision medicine for treatment and biomarker discovery in high-risk hematological malignancies

15:15-15:45 **Brunangelo Falini** (Perugia): Impact of anti-NPM1 monoclonal antibodies in the characterization of NPM1-mutated AML

15:45-16:30 **Jean Paul Thiery** (Singapore): Development of differentiation and immunotherapy strategies interfering with bladder carcinoma progression

16:30-16:45 **Line Bjørge** (Co-Director of CCBIO): Closing remarks



10th CCBIO ANNUAL SYMPOSIUM – MAY 10-11, 2022

Solstrand Hotel & Bad // Bergen // Norway + online

DAY 1: TUESDAY MAY 10, 2022

09:00-09:45 REGISTRATION AND COFFEE

09:45-10:00 **Lars A. Akslen** (Director of CCBIO): Welcome and Opening

Session 1. Chair: **Bjørn Tore Gjertsen**

10:00-11:00 **Robert S. Langer** (Cambridge, MA): From a 1976 Nature paper to a 2020 mRNA vaccine: How overcoming scepticism and barriers led to new cancer treatments and the solution to a global health challenge

11:00-11:30 **Olli Kallioniemi** (Stockholm): Functional and data-driven precision medicine in acute myeloid leukemia

11:30-12:00 **Malin Sund** (Umeå): Early detection of pancreatic cancer

12:00-12:30 **Daniel Öhlund** (Umeå): Targeting tumor-stromal interactions in pancreatic cancer

12:30-14:30 LUNCH AND POSTER SESSION I

Session 2. Chair: **Roger Strand**

14:30-15:45 Imaginaries of precision oncology. Panel: **Marta Bertolaso** (Roma), **Anne Blanchard** (Bergen), **Dominique Chu** (Canterbury) and **Bjørn Hofmann** (Gjøvik, Oslo)

15:45-16:30 COFFEE BREAK

Session 3. Chair: **Oddbjørn Straume**

16:30-17:00 **Carina Strell** (Uppsala/Stockholm): Tumor-stroma interactions driving the progression and therapyresistance of DCIS

17:00-17:30 **Christine Desmedt** (Leuven): Unraveling disease progression and treatment resistance in patients with lobular breast cancer

19:30 DINNER



DAY 2: WEDNESDAY MAY 11, 2022

Session 4

- 09:00-09:45 **Gooitzen van Dam** (Groningen): Clinical molecular imaging: a multidisciplinary tool in cancer treatment from drug development, image-guided surgery to cancer pathology
- 09:45-10:15 **Sébastien Wälchli** (Oslo): From classic to modern CAR repertoire
- 10:15-10:45 COFFEE BREAK

Session 5. Chair: Jim Lorens

- 10:45-11:15 **Srinivas Malladi** (Dallas): Uncovering targetable vulnerabilities of breast cancer brain metastatic cells
- 11:15-11:45 **Rolf Brekken** (Dallas): Restoring sensitivity to immune checkpoint blockade through inhibition of AXL
- 11:45-14:00 LUNCH AND POSTER SESSION II

Session 6. Chairs: Liv C. V. Thomsen and Line Bjørge

- 14:00-15:15 Speed presentations by young investigators

Session 7. Chair: Dana Costea

- 15:15-15:45 **Matthias Nees** (Turku): Automated tracking of tumor-stroma morphology in microtissues identifies targets within the tumor microenvironment for therapeutic intervention
- 14:45-16:15 **Silvio Gutkind** (La Jolla, CA, digitally): Targeting the PIK3CA-mTOR network in head and neck cancer: New multimodal precision immunotherapies
- 16:15-16:30 **Roger Strand** (CCBIO PI): Closing remarks



9th CCBIO ANNUAL SYMPOSIUM – MAY 19-20, 2021

Virtual event in Zoom

(The 8th Symposium in 2020 was cancelled due to the pandemic)

DAY 1: WEDNESDAY MAY 19, 2021

10:00-10:15 **Lars A. Akslen** (Director of CCBIO): Welcome and opening

Session 1. Chairs: **Karl-Henning Kalland** and **Oddbjørn Straume**

11:00-11:45 **Klaus Pantel** (Hamburg): Liquid Biopsy: From discovery to clinical implementation

11:45-12:15 **Ulf Landegren** (Uppsala): Molecular tools for biomarker analysis in immune oncology

12:15-12:45 **Lewis Au** (London): Determinants of anti-PD1 response and resistance in renal cell carcinoma

12:45-13:00 Questions and Discussion

13:00-14:00 BREAK

Session 2. Chairs: **Camilla Krakstad** and **Liv Cecilie Vestrheim Thomsen**

14:00-15:00 Speed presentations by young investigators (replacing posters)

15:00-16:00 BREAK

Session 3. Chairs: **Jim Lorens** and **Rolf Brekken**

16:00-16:45 **Bernd Bodenmiller** (Zürich): Highly multiplexed imaging of tissues with subcellular resolution by imaging mass cytometry

16:45-17:15 **Morag Park** (Montreal): Tumor zonation and immune microenvironments in triple negative breast cancer

17:15-17:45 **Ezra Cohen** (San Diego, CA): Neoantigen identification and use as biomarkers

17:45-18:15 **Genevieve Boland** (Boston): Multi-modality approach to predicting and monitoring immunotherapy response and resistance

18:15-18:30 Questions and Discussion



DAY 2: THURSDAY MAY 20, 2021

Session 4. Chairs: Daniela Costea and Agnete Engelsen

- 11:00-11:50 **Hans Clevers** (Utrecht): Organoids to model human diseases
11:50-12:10 **Daniela Costea** (Bergen): 3D organotypic models of human squamous cell carcinoma
12:10-12:40 **Amir Aref** (Boston): Patient derived organoids in cancer research
12:40-13:00 Questions and Discussion
13:00-14:00 BREAK

Session 5. Chairs: Elisabeth Wik and Cornelia Schuster

- 14:00-15:00 Speed presentations by young investigators (replacing posters)
15:00-16:00 BREAK

Session 6. Chairs: Line Bjørge and Bjørn Tore Gjertsen

- 16:00-16:30 **Anil Sood** (Houston): Ovarian cancer – understanding the mechanisms of adaptive resistance to anti-angiogenesis drugs
16:30-17:00 **Jeffrey Pollard** (Edinburgh): Monocyte regulation in homeostasis and malignancy
17:00-17:30 **Kara Davis** (Palo Alto, CA): Understanding childhood leukemia through the lens of normal development: Single-cell studies for clinical translation
17:30-18:00 **Hani Gabra** (London): Regulation of receptor tyrosine kinases by OPCML – biology and potential therapies
18:00-18:15 Questions and Discussion
18:15-18:30 **Bjørn Tore Gjertsen** (Co-Director of CCBIO): Closing remarks



7th CCBIO ANNUAL SYMPOSIUM – MAY 13-14, 2019

Solstrand Hotel & Bad // Bergen // Norway

DAY 1: MONDAY MAY 13, 2019

09:00-10:00 REGISTRATION AND COFFEE

10:00-10:15 **Lars A. Akslen** (Director of CCBIO): Introduction to the CCBIO Symposium 2019

Chair: Bjørn Tore Gjertsen

10:15-11:00 **Bob Löwenberg** (Rotterdam): Directions in the treatment of acute myeloid leukemia

11:00-11:45 **William D. Foulkes** (Montreal): How do we identify those at risk for hereditary cancer?

11:45-12:30 **Vicky Seewaldt** (South Pasadena, CA): Systems biology approach to improve survival of Black and Latina women with biologically aggressive breast cancer

12:30-14:30 LUNCH AND POSTER SESSION I

Chair: Mark LaBarge

14:30-15:15 **Jonathan Irish** (Nashville): Hacking the signals that control cell identity using single cell mass cytometry

15:15-15:45 **Nick Tobin** (Stockholm): Assessing the clinical relevance of gene expression signatures in primary and metastatic breast cancer

15:45-16:15 **Xisong Ke** (Bergen): Discovery and target identification of anti-cancer drugs

16:15-16:45 COFFEE BREAK

Chair: Roger Strand

16:45-17:45 **Eirik Tranvåg & Roger Strand** (Bergen): Which patient to treat? An interactive priority setting survey

19:30 DINNER



DAY 2: TUESDAY MAY 14, 2019

Chair: Jean Paul Thiery

- 09:00-09:30 **Marco Davila** (Tampa, FL): Improving the safety and efficacy of CAR-T cell therapies
09:30-10:00 **Randy Watnick** (Boston): Development of a therapeutic peptide that reprograms the tumor immune microenvironment
10:00-10:30 **Duanqing Pei** (Zhejiang): New strategies and molecular insight in cellular reprogramming
10:30-11:00 COFFEE BREAK

Chair: Ian Mills

- 11:00-11:30 **Eric B. Haura** (Tampa, FL): Visualizing protein complexes as molecular diagnostics
11:30-12:00 **Agnete Engelsen** (Bergen): Microenvironment-induced Axl signaling is required for epithelial phenotypic plasticity
12:00-12:30 **Alea Mills** (New York): Strengths & vulnerabilities of human glioma
12:30-13:00 **Caroline Heckman** (Helsinki): Bone marrow stroma derived factors and other mechanisms of resistance to therapy in hematological malignancies
13:00-14:45 LUNCH AND POSTER SESSION II

Philosophy of Cancer. Chair: Roger Strand

- 14:45-15:15 **Marta Bertolaso** (Rome): Models and explanations in cancer research

Translation & Innovation. Chair: Yves Aubert

- 15:15-15:30 **Yves Aubert** (Bergen): Creating impact through innovation
15:30-16:30 Volterra Lecture by **Omid Farokhzad** (Bergen): Perspectives on how to translate biomedical research to products and cures (*This keynote address is part of the distinguished Volterra Lectures series organized by Digital Life Norway (DLN). The session is sponsored by CCBIO, Digital Life Norway, VIS, and The Faculty of Medicine, UIB*)
16:30-16:45 **Roger Strand** (CCBIO PI): Closing remarks



6th CCBIO ANNUAL SYMPOSIUM – MAY 23-24, 2018

Solstrand Hotel & Bad // Bergen // Norway

DAY 1: WEDNESDAY MAY 23, 2018

09:00-10:00 REGISTRATION AND COFFEE

10:00-10:15 **Lars A. Akslen** (Director of CCBIO): Introduction to the CCBIO Symposium 2018

Chair: Randy Watnick

10:15-11:00 **Richard O. Hynes** (Cambridge): Extracellular matrix vulnerabilities in cancer

11:00-11:30 **Bruce Zetter** (Boston): RNA therapy in the treatment of cancer

11:30-12:00 **Frederick Locke** (Tampa): CAR T-cell technology against cancer

12:00-12:30 **Thomas F. Meyer** (Berlin): Do bacterial pathogens provoke distinct mutations in their host?

12:30-14:30 LUNCH AND POSTER SESSION I

Chair: Arne Östman

14:30-15:00 **Therese Sørli** (Oslo): Mouse models for breast cancer progression

15:00-15:30 **Carina Strell** (Uppsala/Stockholm): Exploring stroma characteristics as mediators of breast DCIS progression and as markers for radiation-response

15:30-16:00 **Ian G. Mills** (Oxford/Belfast): Stress response signalling in prostate cancer

16:00-16:30 COFFEE BREAK

Chair: Roger Strand

16:30-17:15 **Leonard Fleck** (East Lansing, MI): Just caring challenges: Visible biomarkers and invisible rationing

17:15-17:45 Comment I: **Oddbjørn Straume**

Comment II: **Ole Frithjof Norheim**

19:30 DINNER



DAY 2: THURSDAY MAY 24, 2018

Chair: Rolf Brekken

- 09:00-09:30 **Sui Huang** (Chicago, IL): Non-genetic heterogeneity and non-linear dynamics of tumors: Why cancer treatment can backfire
- 09:30-10:00 **Mark LaBarge** (Dartmouth, CA): The role of microenvironment in cancer susceptibility and drug tolerance
- 10:00-10:30 **Ole W. Petersen** (Copenhagen): On the candidate cells of origin of human breast cancer
- 10:30-11:00 COFFEE BREAK

Chair: Dana Costea

- 11:00-11:20 **Fanny A. Vatter** (New York): High-dimensional analysis of single human mammary epithelial cells with age
- 11:20-11:40 **Kenneth Finne** (Bergen): Proteomic profiles across breast cancer subtypes
- 11:40-12:00 **Gry S. Haaland** (Bergen): Association of warfarin use with lower overall cancer incidence
- 12:00-12:20 **Liv C. V. Thomsen** (Bergen): Cryoimmunotherapy against cancer – status and outlook
- 12:20-14:20 LUNCH AND POSTER SESSION II

Chair: Karl-Henning Kalland

- 14:20-14:50 **William N. William Jr.** (São Paulo/Houston): Developing personalized cancer prevention and therapy strategies: a clinical trials perspective
- 14:50-15:20 **Christina Fotopoulou** (London): Predictive biomarkers in the surgical treatment of epithelial ovarian cancer
- 15:20-15:50 **Ursula Klingmueller** (Heidelberg): From insights into regulation of erythropoiesis towards optimized treatment of anemia
- 15:50-16:20 **Hrvoje Miletic** (Bergen): Microtubes – communication structures of brain tumor cells
- 16:20-16:30 **Bjørn Tore Gjertsen** (Co-Director of CCBIO): Closing remarks



5th CCBIO ANNUAL SYMPOSIUM – APRIL 19-20, 2017

Solstrand Hotel & Bad // Bergen // Norway

DAY 1: WEDNESDAY APRIL 19, 2017

09:00-10:00 REGISTRATION AND COFFEE

10:00-10:15 **Lars A. Akslen** (Director of CCBIO): Introduction to the CCBIO Symposium 2017

Chair: Jean Paul Thiery

10:15-11:00 **John Heymach** (Houston): EMT, immunomodulation and therapeutic resistance

11:00-11:45 **Angela Nieto** (San Juan de Alicante): The partial EMT and cell plasticity in fibrosis and cancer

11:45-12:30 **Robert Gale** (London / Los Angeles): What precisely is precision oncology and will it work?

12:30-14:30 LUNCH AND POSTER SESSION I

Young investigators. Chair: Bjørn Tore Gjertsen

14:30-14:50 **Erling A. Høivik** (Bergen): The genetic evolution of endometrial cancer metastasis

14:50-15:10 **Randi Hovland** (Bergen): Liquid biopsy biomarkers in clinical trials

15:10-15:30 **Oddmund Nordgård** (Stavanger): Liquid biopsies in pancreatic cancer

15:30-15:50 **Thomas Arnesen** (Bergen): N-terminal acetyl-transferases - novel cancer drug targets

15:50-16:10 **Eirik Tranvåg** (Bergen): Biomarkers and potential impact on priority setting

16:10-16:40 COFFEE BREAK

16:40-16:50 **Roger Strand** (Bergen): Book Presentation: "Cancer Biomarkers: Ethics, Economics, and Society"

Chair: Oddbjørn Straume

16:50-17:20 **Diane Bielenberg** (Boston): Expression of neuropilins in the epithelium and endothelium are biomarkers of cancer progression

17:20-17:50 **Kristin Taskén** (Oslo): What's up with adrenergic receptor signaling and prostate cancer?

19:30 DINNER



DAY 2: THURSDAY APRIL 20, 2017

Chair: Donald Gullberg


- 09:00-09:45 **Carl Henrik Heldin** (Uppsala): Signaling via TGF β receptors: possible targets in tumor treatment
- 09:45-10:15 **Jean-Christophe Bourdon** (Dundee): The cell response to anticancer drugs is defined by the p53 protein isoforms in mutant TP53 cells
- 10:15-10:45 **Krister Wennerberg** (Copenhagen): Systems medicine methods for identification of stratified leukemia therapies and their predictive biomarkers
- 10:45-11:15 COFFEE BREAK

Chair: Karl-Henning Kalland

- 11:15-11:45 **Salem Chouaib** (Paris): Effect of hypoxic stress on the cytotoxic anti-tumor response
- 11:45-12:15 **Spiros Kotopoulos** (Bergen): Targeting cells with ultrasound: from theory to reality
- 12:15-14:15 LUNCH AND POSTER SESSION II

Chair: Emmet McCormack

- 14:15-14:45 **Frédéric Amant** (Leuven): Patient derived xenografts as a preclinical model
- 14:45-15:15 **Janine Terra Erler** (Copenhagen): ECM remodelling during cancer progression
- 15:15-15:45 **Jeanette Wood**: Role of pharma, biotech, academia and funding bodies in drug discovery innovation
- 15:45-16:00 **Bjørn Tore Gjertsen** (Co-Director of CCBIO): Closing remarks



4th CCBIO ANNUAL SYMPOSIUM – MAY 10-11, 2016

Solstrand Hotel & Bad // Bergen // Norway

DAY 1: TUESDAY MAY 10, 2016

09:00-10:00 REGISTRATION AND COFFEE

10:00-10:15 **Lars A. Akslen** (Director of CCBIO): Introduction to the CCBIO Symposium 2016

Chair: Lars A. Akslen

10:15-11:00 **Marsha A. Moses** (Boston): Mining the human proteome: Biomarker discovery for human cancer and its metastases

11:00-11:45 **Meenhard Herlyn** (Philadelphia): Tumor microenvironment and drug resistance

11:45-12:30 **Brunangelo Falini** (Perugia): NPM1-mutated acute myeloid leukemia: biological and clinical features

12:30-14:30 LUNCH AND POSTER SESSION I

Young investigators. Chair: Randy Watnick

14:30-14:50 **Elisabeth Wik** (Bergen): An angio-immunogenic profile of basal-like breast cancer; relevance of cancer testis antigens

14:50-15:10 **Siver Moestue** (Trondheim): Imaging-based biomarkers in breast cancer

15:10-15:30 **Guro Lind** (Oslo): Identifying and developing DNA methylation cancer biomarkers for clinical use

15:30-15:50 **Kelly Seo** (London): Impact of cancer biomarkers on the cost-effectiveness of targeted therapies, focusing on mCRC/metastatic colorectal cancer

15:50-16:45 COFFEE BREAK

Chair: Donald Gullberg

16:45-17:15 **Ritva Heljasvaara** (Oulu): Collagen XVIII in breast cancer - a regulator of growth factor receptor-integrin crosstalk and a therapeutic target

17:15-17:45 **Anne Blanchard** (Bergen): Cancer biomarkers looking for patients

19:00 DINNER



DAY 2: WEDNESDAY MAY 11, 2016

Chair: Jim Lorens

- 09:00-09:30 **Karl Johan Malmberg** (Oslo): Allogeneic natural killer cell therapy against high-risk myeloid dysplastic syndrome
- 09:30-10:00 **Rolf Brekken** (Dallas): Phosphatidylserine signaling and immune suppression in the tumor microenvironment
- 10:00-10:30 **Salem Chouaib** (Paris): Hypoxia and the anti-tumor response
- 10:30-11:00 **Michael Curran** (Houston): Hypoxia is an essential driver of immune suppression in the tumor microenvironment
- 11:00-11:30 COFFEE BREAK

Chair: Oddbjørn Straume

- 11:30-12:15 **Thorsten Schlomm** (Hamburg): Diversity of prostate cancer: Implication for translational research
- 12:15-12:45 **Hani Gabra** (London): OPCML, a negative regulator of receptor Tyrosine kinases in ovarian cancer: new biology, new therapy?
- 12:45-14:30 LUNCH AND POSTER SESSION II

Young investigators. Chair: Bjørn Tore Gjertsen

- 14:30-14:50 **Emmet McCormack** (Bergen): Avatars and imaging in cancer therapy development
- 14:50-15:10 **Camilla Krakstad** (Bergen): Exploring biomarkers for endometrial cancer
- 15:10-15:30 **Dana Costea** (Bergen): Effects of nanodiamond modified copolymer scaffolds on tumor progression
- 15:30-15:50 **Ingfrid Haldorsen** (Bergen): Imaging biomarkers relevant for angiogenesis in endometrial cancer
- 15:50-16:05 **Xisong Ke** (Bergen): Cancer therapy: Identification of novel targets
- 16:05-16:15 **Bjørn Tore Gjertsen** (Co-Director of CCBIO): Closing remarks



3rd CCBIO ANNUAL SYMPOSIUM – MAY 19-20, 2015

Solstrand Hotel & Bad // Bergen // Norway

DAY 1: TUESDAY MAY 19, 2015

09:00-10:00 REGISTRATION AND COFFEE

10:00-10:15 **Lars A. Akslen** (Director of CCBIO): Introduction to the CCBIO Symposium 2015

Chair: James Lorens

10:15-11:00 **Jean Paul Thiery** (Singapore): Epithelial-mesenchymal transition (EMT)-based therapeutic strategies in cancer

11:00-11:45 **Thomas Brabletz** (Erlangen): Cellular plasticity in cancer: driving force and therapeutic target

11:45-12:15 **Randolph Watnick** (Boston): The role of Notch1 and p53 in modulating the cancer stem cell phenotype

12:15-14:15 LUNCH AND POSTER SESSION I

Chair: Roger Strand

14:15-14:45 **John Cairns** (London): Challenges in valuing the benefits of new cancer therapies

14:45-15:15 **Ole Frithjof Norheim** (Bergen): Valuing the benefits of new therapies: recommendations from the third national committee on priority setting in Norway

15:15-15:45 **Roger Strand** (Bergen): Sociotechnical imaginaries of cancer biomarkers - a preliminary analysis

15:45-16:15 COFFEE BREAK

Chair: Rolf Reed

16:15-16:45 **Thorarinn Gudjonsson** (Reykjavik): Cellular processes during breast morphogenesis and EMT: an approach from 3D culture

16:45-17:15 **James Lorens** (Bergen): Multipotent mammary stem cell activity requires Axl receptor tyrosine kinase

17:15-17:45 **Karl-Henning Kalland** (Bergen): Prostate cancer - new therapeutic approaches

19:00 DINNER



DAY 2: WEDNESDAY MAY 20, 2015

Chair: Arne Östman

09:00-09:45 **David Tuveson** (New York): Pancreatic cancer models and medicine

09:45-10:15 **Arne Östman** (Stockholm): Cancer-associated fibroblasts and pericytes as sources of prognostic and predictive information

10:15-10:45 **Per Ø. Enger** (Bergen): Brain tumor stroma interactions from a translational perspective

10:45-11:15 COFFEE BREAK

Chair: Helga Salvesen

11:15-12:00 **Ravi Bhatia** (Birmingham, Al): Targeting leukemia stem cells in myeloid malignancies

12:00-12:30 **Bjørn Tore Gjertsen** (Bergen): Biomarkers in individualized cancer trials – hype or future cancer care?

12:30-14:15 LUNCH AND POSTER SESSION II

Chair: Karl-Henning Kalland

14:15-15:00 **Klaus Pantel** (Hamburg): Liquid biopsy: Implications for cancer therapy

15:00-15:30 **Odd Helge Gilja** (Bergen): Ultrasound sonoporation applied experimentally and in patients with pancreatic adenocarcinoma

15:30-16:00 **Guttorm Haraldsen** (Oslo): Interleukin-33 - an important factor in stromal inflammation

16:00-16:30 **Nils Halberg** (Bergen): A microRNA regulon that mediates breast cancer metastasis

16:30-16:45 **Lars A. Akslen** (Bergen): Closing remarks



2nd CCBIO ANNUAL SYMPOSIUM – MARCH 25-26, 2014

Solstrand Hotel & Bad // Bergen // Norway

DAY 1: TUESDAY MARCH 25, 2014

09:00-10:00 REGISTRATION AND COFFEE

10:00-10:15 **Lars A. Akslen** (Director of CCBIO): Introduction to the CCBIO Symposium 2014

Chair: James Lorens

10:15-11:00 **Rameen Beroukhim** (Boston): Interpreting cancer copy-number alterations

11:00-11:30 **Helga Salvesen** (Bergen): Molecular profiling of primary compared to metastatic lesions in gynecologic cancers

11:30-12:00 **Therese Sørli** (Oslo): Gene expression patterns and biomarkers in subtypes of breast cancer

12:00-14:00 LUNCH AND POSTER SESSION I

Chair: Donald Gullberg

14:00-14:45 **Mark LaBarge** (San Francisco): Insights into aging and cancer through deconstruction and recapitulation of human mammary microenvironments in culture

14:45-15:15 **James Lorens** (Bergen): The role of the Axl receptor tyrosine kinase in drug resistance and metastasis

15:15-15:45 COFFEE BREAK

15:45-16:15 **Ian Mills** (Oslo): An interplay between transcription and metabolic reprogramming in prostate cancer

16:15-16:45 **Karl-Henning Kalland** (Bergen): Cancer cell heterogeneity and reprogramming plasticity – therapeutic possibilities

19:00 DINNER




DAY 2: WEDNESDAY MARCH 26, 2014

Chair: Helga B. Salvesen

- 09:00-09:45 **Valerie Weaver** (San Francisco): Tissue tension reprograms the tissue to metastasis
- 09:45-10:15 **Donald Gullberg** (Bergen): Fibroblast integrins in wounds, scars and tumors – emerging molecular themes
- 10:15-10:45 **Randolph Watnick** (Boston): Development of a novel multimodal therapeutic agent targeting the tumor microenvironment
- 10:45-11:15 COFFEE BREAK
- 11:15-12:00 **Johanna Ivaska** (Turku): Cell-matrix interactions in cancer
- 12:00-12:45 **Taina Pihlajaniemi** (Oulu): Multiplexin collagens in development and maintenance of tissue homeostasis and in malignant growth
- 12:45-14:15 LUNCH AND POSTER SESSION II

Chair: Karl-Henning Kalland

- 14:15-14:45 **Bruce Zetter** (Boston): New approaches to metastatic cancer
- 14:45-15:15 **Kjetil Taskén** (Oslo): Regulation of anti-tumor immune responses in colorectal cancer
- 15:15-15:45 **Bjørn Tore Gjertsen** (Bergen): Personalized medicine and clonal evolution in acute leukemia?
- 15:45-16:00 **Lars A. Akslen** (Bergen): Closing remarks



OPENING SYMPOSIUM – MAY 30-31, 2013

Store auditorium // Haukeland University Hospital // Bergen // Norway

DAY 1: THURSDAY MAY 30, 2013

12:30-13:00 REGISTRATION, COFFEE AND LIGHT FOOD

Session 1, Welcome and official opening. Chair: Dean Nina Langeland

13:00-13:30 Welcoming announcement and short presentation of the Centre for Cancer Biomarkers by CCBIO's Director, **Lars A. Akslen** (University of Bergen)

13:30-14:30 Official opening, short speeches and congratulatory statements

14:30-15:00 COFFEE AND LIGHT FOOD

Session 2, Biomarkers: Tradition and Future. Chair: Rolf Reed

15:00-15:45 Keynote lecture I: **Bruce Zetter** (Harvard Medical School): New mechanisms and biomarkers of chemoresistance

15:45-16:30 Keynote lecture II: **Mina Bissell** (Lawrence Berkeley National Laboratory): Engineered models of dormancy and metastasis: the importance of the extracellular matrix

DAY 2: FRIDAY MAY 31, 2013

Session 3, Biomarkers: Ethical, legal and economic aspects. Chair: Oddvar Kaarbøe

10:00-10:30 Keynote lecture III: **John Cairns** (London School of Hygiene & Tropical Medicine): The economic evaluation of cancer biomarkers

10:30-11:30 **Roger Strand** (University of Bergen): From ethics to ELSA of research on cancer biomarkers
Oddvar Martin Kaarbøe (University of Bergen): Economic aspects of biomarkers
Comments by **Ole Frithjof Nordheim** (University of Bergen)

11:30-13:00 LUNCH & POSTER SESSION, ASSEMBLY HALL, BBB

Session 4, Biomarkers: From basic to clinical studies. Chair: Bjørn Tore Gjertsen

13:00-15:00 **Arne Östman** (Karolinska Institute): PDGF-dependent CAFs and pericytes; impact on metastasis and prognosis
Christopher Hughes (University of California Irvine): Angiogenesis and the tumor microenvironment

Randolph Watnick (Harvard Medical School): Development of a novel therapeutic peptide for the treatment of advanced cancer

Rolf Brekken (University of Texas): Macrophages and metastasis: targeting prometastatic macrophages and the products they make

Ate van der Zee (University of Groningen): Examples of biomarker research in gynaecologic oncology

15:00-15:30 COFFEE BREAK

15:30-17:30 **George N. Naumov** (Merck Research Laboratories Boston): Development and biomarker strategy of novel combination therapies using two investigational oncology agents

Oddbjørn Straume (University of Bergen): Angiogenesis as a treatment target in metastatic melanoma

Biaoyang Lin (University of Washington): Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identified by a next-generation sequencing-based approach

James Lorens (University of Bergen): Stem cells, EMT and cancer: The role of the Axl receptor

17:30-17:35 **Lars A. Akslen**: Summing up and closing

